Ultime notizie per NexPoint Residential (NYSE:NXRT) Azioni

NexPoint Residential

NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.

NexPoint Residential Trust, Inc. Common Stock

NexPoint Residential Trust Inc

Biogen presentations include a late breaking oral presentation highlighting the conclusive data from the Phase 2 IGNAZ study of felzartamab for IgA nephropathy (IgAN).&nbsp;

News

BIIB

Biogen Plans To Present Variety Of New Data From Its Felzartamab Clinical Development Program At Kidney Week 2024

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 3</a>0, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Organon &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>)</h3>
<ul>
<li>Organon will release its third quarter 2024 financial results on Oct. 31. The company's stock fell around 12% over the past month and has a <a href="https://www.benzinga.com/quote/OGN">52-week low of $10.84</a>.</li>
<li>RSI Value: 28.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>OGN Price Action: Shares of Organon fell 0.9% to close at $17.45 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">latest OGN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="907" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197.png" alt="" class="wp-image-607146" style="width:757px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197-768x710.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></figure>
<h3 class="wp-block-heading">Arcutis Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>)&nbsp;</h3>
<ul>
<li>On Oct. 21, Arcutis Canada announced Health Canada approval of ZORYVE&#xAE; Foam to treat seborrheic dermatitis in individuals 9 years of age and older. Dr. Melinda Gooderham, medical director at the SKiN Centre for Dermatology and a principal Canadian investigator in the pivotal Phase 3 STRATUM trial said, &#8220;The approval of ZORYVE foam by Health Canada is a significant development in the management of this condition. Clinical trial data show close to 80% of patients achieving treatment success at week 8 and rapid itch relief in as little as 48 hours.&#8221; The company's stock fell around 14% over the past five days and has a 52-week low of $1.76.</li>
<li>RSI Value: 28.13</li>
<li>ARQT Price Action: Shares of Arcutis Biotherapeutics fell 4.7% to close at $8.31 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">trend in ARQT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192.png" alt="" class="wp-image-606848" style="width:703px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192-768x704.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">TransMedics Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>)</h3>
<ul>
<li>TransMedics Group will release financial results for the third quarter after market close on Monday, Oct. 28. The company's shares fell around 22% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/MGRX">low of $36.42</a>.</li>
<li>RSI Value: 29.60</li>
<li>TMDX Price Action: Shares of TransMedics fell 1.7% to close at $124.48 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">breakout in TMDX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="818" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193.png" alt="" class="wp-image-606851" style="width:702px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193-768x696.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41429862/this-analyst-with-85-accuracy-rate-sees-around-11-upside-in-netflix-here-are-5-stock-picks-for-last">This Analyst With 85% Accuracy Rate Sees Around 11% Upside In Netflix &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

ARQT

TMDX

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) reported quarterly earnings of $0.46 per share which met the analyst consensus estimate. This is a 9.8 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $485.862 million which beat the analyst consensus estimate of $482.156 million by 0.77 percent. This is a 6.54 percent increase over sales of $456.024 million the same period last year.

Earnings

Earnings Beats

Old National Q3 2024 Adj. EPS $0.46, Inline, Sales $485.862M Beat $482.156M Estimate

2024 Financial Outlook
The following table and other sections of this news release contain forward-looking statements, which are based on the company&#39;s current expectations. Actual results may differ materially from those projected. It is the company&#39;s practice not to incorporate adjustments into its financial outlook for proposed or potential acquisitions, divestitures, ventures, pension risk transfer transactions or discretionary contributions, financing transactions, changes in law, or new accounting standards until such items have been consummated, enacted or adopted. For additional factors that may impact the company&#39;s actual results, refer to the &quot;Forward-Looking Statements&quot; section in this news release.
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
(in millions, except per share data)
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Current Update1
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
July 2024
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Net sales
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$71,250
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$70,500 - $71,500
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Business segment operating profit2
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$7,475
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$7,350 - $7,500
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Total FAS/CAS pension adjustment
</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,685
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,685
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Diluted earnings per share3
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$26.65
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$26.10 - $26.60
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Cash from operations
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$7,950
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$7,750 - $8,050
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Capital expenditures
</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,750
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,750
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Free cash flow2
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$6,200
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$6,000 - $6,300
</td>
</tr>
</tbody>
</table>

Guidance

Lockheed Martin Raises FY24 Outlook: GAAP EPS from $26.10-$26.60 to $26.65 vs $26.38 Est; Narrows Sales Guidance from $70.50B-$71.50B to $71.25B vs $71.05B Est

SNGX

Soligenix Says Hong Kong Patent Office Has Granted Patent Entitled 'Systems And Methods For Producing Synthetic Hypericin'

WIIM

HYZN

Hyzon shares are trading higher after the company announced a purchase agreement for 12 hydrogen-powered refuse Fuel Cell Electric Vehicles with GreenWaste.

Contracts

Hyzon Enters Purchase Agreement With GreenWaste For 12 Fuel Cell Electric Vehicles

The transaction is expected to close in the&nbsp;fourth quarter&nbsp;of 2024, subject to customary closing conditions.

Asset Sales

MGNX

MacroGenics Enters Agreement With TerSera For Sale Of Global Rights Of MARGENZA; $40M To Be Paid At Closing And May Receive Additional Sales Milestone Payments Of Up To Of $35M

Biotech

General

MacroGenics Enters Agreement With TerSera Therapeutics, Under Which TerSera Will Acquire Global Rights To MARGENZA; TerSera To Pay MacroGenics $40M At Closing And MacroGenics May Receive Milestones Up To $35M

As previously announced on Oct. 2, 2024, the company&#39;s board authorized the repurchase of its common stock up to an additional $3.0 billion, increasing the total authorization for potential future common stock repurchases to $10.3 billion. The stock repurchase program does not have an expiration date and may be amended or terminated by the board of directors at any time. The amount of shares ultimately purchased and the timing of purchases are at the discretion of management and subject to compliance with applicable law and regulation.

Buybacks

Lockheed Martin Increased Stock Buyback Authorization By $3B To $10.30B On Oct. 2

Dime Community Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCOM#NASDAQ">DCOM</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.41 by 29.27 percent. The company reported quarterly sales of $87.555 million which beat the analyst consensus estimate of $78.147 million by 12.04 percent. This is a 3.73 percent increase over sales of $84.407 million the same period last year.

Earnings Misses

DCOM

Dime Community Bancshares Q3 2024 Adj. EPS $0.29 Misses $0.41 Estimate, Sales $87.555M Beat $78.147M Estimate

SIGA

SIGA Enters Exclusive License Agreement With Vanderbilt University To Obtain A License To A Portfolio Of Preclinical Fully Human Poxvirus Monoclonal Antibodies

Baird analyst Joe Vruwink maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Outperform and raises the price target from $216 to $226.

Price Target

Analyst Ratings

Baird Maintains Outperform on PTC, Raises Price Target to $226

Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) reported quarterly earnings of $6.84 per share which beat the analyst consensus estimate of $6.50 by 5.23 percent. This is a 1.03 percent increase over earnings of $6.77 per share from the same period last year. The company reported quarterly sales of $17.104 billion which missed the analyst consensus estimate of $17.351 billion by 1.42 percent. This is a 1.34 percent increase over sales of $16.878 billion the same period last year.

Lockheed Martin Q3 2024 Adj. EPS $6.84 Beats $6.50 Estimate, Sales $17.104B Miss $17.351B Estimate

Southern First Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFST#NASDAQ">SFST</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.38 by 42.11 percent. The company reported quarterly sales of $20.59 million which missed the analyst consensus estimate of $20.81 million by 1.05 percent. This is a 6.44 percent increase over sales of $19.34 million the same period last year.

SFST

Southern First Bancshares Q3 2024 GAAP EPS $0.54 Beats $0.38 Estimate, Sales $20.59M Miss $20.81M Estimate

On Monday, October 21st, U.S. markets closed mixed, with the Dow and S&amp;P 500 declining. This ended a six-week winning streak as rising Treasury yields and high valuations raised investor caution ahead of key earnings reports. Nvidia boosted the Nasdaq, while Tesla and other rate-sensitive tech stocks slipped.
Boeing surged as news emerged that <a target="_blank" href="https://www.benzinga.com/news/24/10/41433623/boeing-stock-rises-ahead-of-wednesdays-union-vote-will-investors-breathe-a-sigh-of-relief" rel="noreferrer noopener">workers might vote</a> on a deal to end a costly five-week strike, while Spirit Airlines <a target="_blank" href="https://www.benzinga.com/news/24/10/41432467/why-spirit-airlines-stock-is-taking-off-monday" rel="noreferrer noopener">soared after securing an agreement</a> to extend its debt refinancing deadline by two months.
Most S&amp;P 500 sectors closed lower on Monday, with real estate, health care, and financials leading the losses. Meanwhile, tech stocks outperformed, finishing higher.
The Dow Jones Industrial Average declined 0.80% and closed at 42,931.60. The S&amp;P 500 ended the day lower by 0.18% at 5,853.98, while the Nasdaq Composite rose 0.27%, finishing the session at 18,540.01.
Asia Markets Today
<ul>
<li>On Tuesday, Japan&#8217;s Nikkei 225 closed lower by 1.60% at 38,405.50, led by 38,405.50, led by losses in the Chemical, Petroleum &amp; Plastic, Rubber and Power sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 declined 1.68% and ended the day at 8,205.70, led by losses in the Healthcare, A-REITs and Consumer Discretionary sectors.</li>
<li>India&#8217;s Nifty 50 traded lower by 1.25% at 24,472.10, and Nifty 500 was down 1.93% at 22,814.45.</li>
<li>China&#8217;s Shanghai Composite rose 0.54% to close at 3,285.87, and the Shenzhen CSI 300 gained 0.57%, finishing the day at 3,957.78.</li>
<li>Hong Kong&#8217;s Hang Seng gained 0.10% and closed the session at 20,498.95.</li>
</ul>
Eurozone at 06.00 AM ET
<ul>
<li>The European STOXX 50 index was down 0.47%.</li>
<li>Germany&#8217;s DAX declined 0.22%.</li>
<li>France&#8217;s CAC fell 0.80%.</li>
<li>U.K.&#8217;s FTSE 100 traded lower by 0.74%.</li>
</ul>
Commodities at 06.00 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.94% at $70.69/bbl, and Brent was up 0.82% at $74.90/bbl.</li>
<li>Oil prices steadied as U.S. diplomatic efforts to push for a Middle East ceasefire and weak demand growth in China weighed on the market.</li>
<li>Natural Gas was up 1.60% at $2.348.</li>
<li>Gold was trading higher by 0.27% at $2,746.15, Silver rose 0.92% to $34.392, and Copper gained 0.67% to $4.3885.</li>
<li>Gold prices rose near record highs amid uncertainty about the U.S. election, Middle East tensions, and expected interest rate cuts.</li>
</ul>
U.S. Futures at 06.00 AM ET
Dow futures were down 0.47%, S&amp;P 500 futures fell 0.01%, and Nasdaq 100 Futures slid 0.65%.
Forex at 06.00 AM ET
The U.S. Dollar Index slid 0.02% to 104.00, USD/JPY was down 0.01% at 150.81, and USD/AUD declined 0.39% to 1.4960.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Mixed, Europe Slips, Gold Near Record High - Global Markets Today While US Slept

Baird analyst Joe Vruwink maintains Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Outperform and raises the price target from $263 to $304.

MANH

Baird Maintains Outperform on Manhattan Associates, Raises Price Target to $304

Keybanc analyst Steve Barger initiates coverage on Plexus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) with a Sector Weight rating.

Initiation

PLXS

Keybanc Initiates Coverage On Plexus with Sector Weight Rating

DA Davidson analyst Linda Bolton Weiser maintains Interparfums (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) with a Buy and maintains $163 price target.

IPAR

DA Davidson Maintains Buy on Interparfums, Maintains $163 Price Target

Baird analyst Shrenik Kothari maintains Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) with a Neutral and raises the price target from $200 to $210.

CHKP

Baird Maintains Neutral on Check Point Software, Raises Price Target to $210

Analyst Michael Lewis of Truist Financial maintained a Hold rating on NexPoint Residential (NXRT – Research Report), boosting the price target to $...

NexPoint Residential Trust: Hold Rating with Revised Price Target Amid Mixed Growth Projections

Dividend Champion, Contender, And Challenger Highlights: Week Of September 8

Leverage In Real Estate Investing

The State Of REITs: September 2024 Edition

Dividend Champion, Contender, And Challenger Highlights: Week Of September 22

SA Chart: Which sector will benefit the most from interest rate cuts?

TCW Global Real Estate Fund Q2 2024 Commentary

An October Surprise

Raymond James analyst Buck Horne upgraded NexPoint Residential (NXRT) to Outperform from Market Perform with a $50 price target The firm cites "res...

Comments

NexPoint Residential

Notizie

Ultime notizie per NexPoint Residential (NYSE:NXRT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO